Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis.
about
Targeted therapies and immunotherapy in non-small-cell lung cancerUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsTyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis.New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies.Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation.Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancerPrevalence of EGFR Mutations in Lung Cancer in Uruguayan Population.Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed-carboplatin chemotherapy.Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma.Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer.Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01).Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression.Subjecting appropriate lung adenocarcinoma samples to next-generation sequencing-based molecular testing: challenges and possible solutions.Development of biomarkers for real precision medicine
P2860
Q26738986-D7A921DE-A5B2-4BF1-BD95-8F419AAA44DDQ28075291-D51636E0-C998-4C27-967C-E27D8ABCA603Q33662730-C982BED3-1D72-4B16-BC2B-61C7A489250EQ33704088-4F8DA106-1AB2-48BB-BBA5-76606D94130FQ33779727-F685B00C-1673-4184-B361-6427EA71D108Q35895572-B868FF67-7153-4D6D-8321-4E30A2C2BDF2Q37295811-344F6827-AF2C-485E-BBEB-B9286C9493F2Q37569995-93C2E059-BEE0-40C3-85E7-8D88AA89C558Q37701159-9943599E-3A79-44D9-A58E-9DA15F5F8786Q38661269-7DC1467C-CA52-41E3-8238-77E532380979Q38870678-B3FDFBD1-66AB-4E40-AEB4-7121D9BDB9D1Q39432861-9B606F8C-66A0-40CF-9F05-12E39E1E6DCAQ41092945-CE2445E9-A8E4-4B46-AA84-3D44656E94FBQ47102129-6A05DB0D-255F-48D3-AA73-15D6F56AD35BQ47102256-F110E723-B4C0-45E9-8E79-728B91AD25E8Q47135157-B4157158-E39A-44C3-B140-C840659D0E36Q47261688-1D371068-C9C0-4F15-BA3E-4B4D11589BC7Q47659502-E0EF32F1-CA1A-4F28-A613-DC7AC393737FQ49417517-3C784713-8A9E-4696-9E05-3357A9280430Q49800454-43FDBE8B-6540-4FB0-B79E-CE6A2A8F401CQ52724325-5926C163-8D32-4FDA-B776-135DBADF43FDQ54983901-5F7B2AF8-7504-46DA-A1D6-8D3147CEC645Q55082628-FE9BDDC5-EB45-4AD8-97A4-8D91AFF5A1C6Q58562445-A34B8B37-AAD3-44BC-965C-23110F6F0501
P2860
Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Overall survival benefits of f ...... atic review and meta-analysis.
@en
type
label
Overall survival benefits of f ...... atic review and meta-analysis.
@en
prefLabel
Overall survival benefits of f ...... atic review and meta-analysis.
@en
P2093
P2860
P921
P356
P1476
Overall survival benefits of f ...... matic review and meta-analysis
@en
P2093
Cheng-Ta Yang
Chung-Sheng Shi
David Teng
Feng-Che Kuan
Kuan-Der Lee
Min-Chi Chen
P2860
P2888
P304
P356
10.1038/BJC.2015.356
P407
P5008
P577
2015-10-13T00:00:00Z